Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Prostatic Neoplasms 2Neoplasms 2Lung Neoplasms 2Urinary Bladder Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Peripheral Nervous System Diseases 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Nasopharyngeal Carcinoma 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Gastroesophageal Adenocarcinoma 1Depression 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma 1Anxiety Disorders 1

Interventions

Paclitaxel 328Carboplatin 323Bevacizumab 171Gemcitabine 106liposomal doxorubicin 104pembrolizumab 101Cyclophosphamide 96Topotecan 94olaparib 92Cisplatin 92niraparib 69Docetaxel 57Taxes 52Doxorubicin 51Drug Therapy 45fludarabine 40Filgrastim 39Nivolumab 37Magnetic Resonance Spectroscopy 34Surveys and Questionnaires 33Specimen Handling 33Etoposide 32Hyperthermic Intraperitoneal Chemotherapy 31Blood Specimen Collection 29Immunoglobulin G 27Disulfides 27Peripheral Blood Stem Cell Transplantation 26Cytoreduction Surgical Procedures 25Albumin-Bound Paclitaxel 25durvalumab 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × Single Person × Clear all
NCT02978222 2022-12-15

Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer

Marker Therapeutics, Inc.

Phase 2 Terminated
120 enrolled 12 charts
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡